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Recent studies indicate that propofol may protect cells via suppressing autophagic cell death caused by excessive reactive oxygen
species induced by hypoxia reoxygenation (H/R). It is established that gene expression patterns including autophagy-related genes
changed significantly during the process of H/R in the presence or absence of propofol posthypoxia treatment (P-PostH). The
reasons for such differences, however, remain largely unknown. MicroRNAs provide a novel mechanism for gene regulation. In
the present study, we systematically analyzed the alterations in microRNA expression using human umbilical vein endothelial cells
(HUVECs) subjected to H/R in the presence or absence of posthypoxic propofol treatment. Genome-wide profiling of microRNAs
was then conducted using microRNA microarray. Fourteen miRNAs are differentially expressed and six of them were validated
by the quantitative real-time PCR (Q-PCR) of which three were substantially increased, whereas one was decreased. To gain an
unbiased global perspective on subsequent regulation by altered miRNAs, predicted targets of ten miRNAs were analyzed using
the Gene Ontology (GO) analysis to build signaling networks. Interestingly, six of the identified microRNAs are known to target
autophagy-related genes. In conclusion, our results revealed that different miRNA expression patterns are induced by propofol
posthypoxia treatment inH/R and the alterations inmiRNA expression patterns are implicated in regulating distinctive autophagy-
related gene expression.
1. Introduction
As a result of increased oxidative stress, reperfusion of
ischemic tissues or cells leads to a systemic inflammatory
response which in turn may cause widespread microvas-
cular dysfunction and tissue/cell injury [1–3]. Studies have
shown that the vascular endothelium is a crucial site that
is affected by ischemia/reperfusion (I/R) injury [4–6]. Due
to the instability of the current overall animal model of I/R
injury which is largely affected by multifaceted factors in vivo
and in vitro, animal models thus cannot reflect the exact
protective mechanisms of drugs on the tissue/cell damage.
In vitro cultured endothelial cells, however, are simple and
controllable system that can create useful I/R injury model
[7, 8].
Propofol is a widely used intravenous anesthetic with
antioxidant capacity. It shows protective roles on the hydro-
gen peroxide (H
2
O
2
)-induced apoptosis in cardiac cells and
myocardial ischemia and reperfusion (I/R) injury in rats [9,
10]. Recent evidences have shown that propofol may suppress
the I/R activated autophagic cell death through affecting
the expressions of autophagy-related genes [11–14]. But the
mechanisms of the protective effects of propofol onHUVECs
I/R injury have not been well studied.
MicroRNAs (miRNAs) are an evolutionarily conserved
family of short noncoding RNAs, that negatively regulate
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Figure 1: Build theH/R andP-PostHmodel.The culturemediawere replaced by glucose and serum freeDMEMbalanced in normal incubator
in 30 minutes, and these HUVEC cells were then placed in hypoxic conditions which were created by a small enclosed humidified plexiglass
chamber filled with 94% N
2
, 5% CO
2
, and 1% O
2
at 37∘C for 12 h. After hypoxia, the medium was immediately washed off, and the HUVECs
were returned to the maintenance medium (NCS-DMEM) in normal incubator for 4 h. At the same time, prepared propofol was added to
the medium to different concentrations (25 𝜇mol/L–150𝜇mol/L).
genes in a cell via degradation or translation inhibition of
their target mRNAs [15]. In recent years, many associations
between disease mechanisms and specific miRNAs have
been identified and confirmed using large-scale microarrary
profiling and genetic approaches [16]. Studies provide an
overview of the role of miRNAs in the development of I/R
injury in the heart and kidney [17].However,miRNAs that are
associated with the protective effect of propofol on I/R injury
remain largely unknown.
In the present study, we constructed an in vitro cellular
hypoxia/reperfusion (H/R) model and found that propo-
fol effectively reduced H/R injury. We performed systemic
analysis of the alterations in miRNA expression using
miRNAmicroarray in human umbilical vein endothelial cells
(HUVECs) treated with H/R in the presence or absence
of propofol posthypoxia treatment. Fourteen miRNAs were
shown to be differentially expressed of which eight were
substantially increased, whereas six were decreased and six
of them were picked and further validated by qRT-PCR.
Then, the Gene Ontology (GO) analysis was conducted to
build signaling networks of predicted targets of ten miRNAs.
Interestingly, six of the identified microRNAs are found to
target autophagy-related genes. Our results revealed that
different autophagy-associated miRNA expression patterns
are induced by propofol posthypoxia treatment in H/R,
which implicates that differential autophagy-related gene-
expression regulated by miRNAs may play a role in propofol
posthypoxia treatment in H/R.
2. Results
2.1. Protective Effects of Propofol Posthypoxia Treatment
against H/R Injury on Cell Viability. The construction of the
cellular H/R P-PostH model is shown in Figure 1. The cells
in the control group were considered 100% viable. As shown
in Figure 2(a), there was no marked alteration in propofol-
treated cells compared with control cells under normal
conditions. CCK-8 assay showed that propofol treatment for
4 h at concentrations up to 150𝜇mol/L did not influence
cell viability (𝑃 > 0.05). Exposure of cells to H/R resulted
in reduction of cell viability (Figure 2(b)). The viabilities of
cells in the H/R groups were 55.9 ± 1.8% (𝑃 < 0.01 versus
control). In all the groups of H/R+P-PostH, the viability of
cells increased compared with the H/R only group (𝑃 <
0.05) except 150𝜇mol/L (68.1 ± 5.3, 69.4 ± 3.6, 72.2 ± 5.7,
and 62.5 ± 6.7%, resp.) indicating that administration of
excessive propofol has no protective effects. The results did
not show significant dose-dependent manner compared with
previous reports. This discrepancy may be due to different
experimental condition (e.g., the concentration of oxygen in
hypoxic chamber, the H/R time and different cell lines that
we used).
2.2. Inhibitory Effect of Posthypoxia Treatment with Propofol
on Apoptosis and Autophagy Induced by H/R. To confirm
the inhibitory effect of P-PostH on cell apoptosis, HUVECs
were stained with Annexin V-FITC and propidium iodide,
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Figure 2: Propofol increased the viability and reduced the apoptosis of the H/R induced injury in HUVECs. (a) The normal HUVECs were
treated with different concentrations (0–150 𝜇mol/L) of propofol for 4 h. (b)The cells were postconditioned with increasing concentrations of
propofol (0–150𝜇mol/L) after 12 h of hypoxia and 4 h of reperfusion. Cell viability was determined by CCK-8 assay, as previously described.
Values are represented as the percentage of viable cells; vehicle-treated cells were considered as 100% viable. The data represented are mean
percentage of viable cells + SD of three independent experiments. ∗𝑃 < 0.001, compared with control group, 󳶃𝑃 < 0.05, compared with
the H/R group. (c) Detection of apoptosis with Annexin V-FITC and propidium iodide staining. Every group of cells with Annexin V and
propidium iodide staining was measured by flow cytometry. Histogram representing the percentage of early apoptotic cells and late apoptotic
cells. The data represent the mean + SD of three independent experiments. ∗𝑃 < 0.01, compared with the control group, and 󳶃𝑃 < 0.05 with
H/R group. (d) Expression of apoptosis-related proteins in normal group, H/R injury group, and propofol posthypoxia treatment groups.
Data are representative WB from 3 independent experiments (𝑛 = 2).
and then analyzed by flow cytometry.The percentage of early
apoptosis in the control and H/R groups was 8 + 4.4% and
36.6 + 2.4%, respectively (𝑃 < 0.01 versus control). There
was an obvious reduction in the number of early apoptotic
cells, (25.6 + 2.8, 22.6 + 2.6, 21 + 3.2, 32.2 + 2.5%) when
cells were treated with different concentrations of propofol
(25, 50, 100, 150 𝜇mol/L) respectively, compared with theH/R
group (𝑃 < 0.05 versus H/R group) in Figure 2(c). We then
examined the apoptosis-related proteins by using Western
blotting (WB). Apoptotic protein Bax is upregulated and
PARP is cleaved while anti-apoptotic protein Bcl-2 is down-
regulated upon H/R treatment (Figure 2(d)). However, the
expression of these proteins is reversed and PARP cleavage
is prevented upon adding propofol after hypoxia treatment
in a dose-dependent manner except 150𝜇mol/L, which is
in agreement with the results from the viability assay and
Annexin V-FITC and PI staining (Figure 2(d)).
Next, we investigated whether H/R-induced autophagy
in HUVECs can be regulated by propofol. H/R promoted
effective transition of LC3-I to LC3-II, which was pre-
vented by propofol treatment except 150 𝜇mol/L, compared
with control cells subjected to DMSO during the course
of H/R injury or normoxia (Figures 3(a), 3(b), and 3(c)).
The immunofluorescence observation strengthened the WB
results. HR induced a significant number of LC3 puncta
and irregular shape of mitochondria (indicative apoptosis)
while cells can be recovered to normal state upon propofol
treatment (Figure 3(d)).
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Figure 3: Propofol suppresses the H/R-induced autophagy. (a) The expression of LC3 was determined in normal cells, H/R injury cells,
and propofol posthypoxia treatment cells (25–150 𝜇mol/L). (b) The expression of LC3 was determined in control cells and cells treated by
normoxia with propofol (25–150𝜇mol/L). (c)The expression of LC3was determined in normal cells group,H/R injury cells group, andDMSO
posthypoxia treatment groups (25–150𝜇mol/L). Data are representative WB from 3 independent experiments (𝑛 = 3). (d) Autophagosomes
and mitochondria were probed by anti-LC3 and anti-Tim23 in normal cells, H/R injury cells, and propofol posthypoxia treated cells. Bar,
20 𝜇m.
Together, these data indicate that Propofol could effec-
tively suppress the apoptosis and autophagy induced by the
H/R in HUVECs.
2.3. miRNA Are Differently Expressed in P-Post+H/R Com-
pared with H/R Alone. To study the potential miRNAs that
may function in the protective effect on H/R injury in
HUVECs, we determined the miRNA expression profile
in HUVECs through miRNA microarray analysis. We first
assessed the miRNA expression profiles in the P-PostH and
H/R groups. The expression profiles of hundreds of miRNAs
determined to be regulated between P-Post and H/R separate
samples into biologically interpretable groups. Among these,
8 miRNAs were identified to be upregulated more than two
fold in P-PostH group compared with the same 8 miRNAs
in H/R group, while 6 miRNAs were downregulated more
than twofold (𝑃 < 0.01) (Figure 4). 6 miRNAs among these
filtered ones were selected for qRT-PCR verification, four of
which were validated to be significantly different between the
propofol and HR groups (𝑃 < 0.05). The other two show
the expression tendency consistent with the array result but
without statistical significance. As is shows in Figure 5, the
levels of hsa-miR-30b, hsa-miR-20b, hsa-miR-196a, hsa-miR-
374b were upregulated in propofol-treated group with the
HR only group, while hsa-let-7e and hsa-miR-15b showed an
opposite expression pattern, whichwas in agreement with the
result of microarray hybridization.
2.4. Potential Autophagy-Related Targets of the Differentially
Expressed miRNAs Are Revealed. Computational algorithms
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Figure 4: miRNA profiles differentiate the propofol group from the H/R group. (a) Hierarchical clustering of 14 miRNAs whose expression
was significantly altered (fold change >2, 𝑃 < 0.01, FDR > 0.05) in the propofol and HR groups.The color stands for the intensity of the signal
(𝑛 = 3). (b) In the scatter diagram, red spots stand for themiRNAs expressed higher in the HR group, the green ones stand for the ones higher
in the propofol groups, and the black ones with no significant changes.
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Table 1: The targets and the expression levels of microRNAs.
miRNA Target symbol Target common name Miranda TargetScan HR expression level
miRNA
hsa-miR-30b BECN1 Beclin 1, autophagy related Yes Yes ↓
hsa-miR-30b ATG5 Autophagy related 5 Yes Yes ↓
hsa-miR-20b ULK1 unc-51 like autophagy activating kinase 1 Yes Yes ↓
hsa-miR-20b MAP3K14 mitogen-activated protein kinase kinase kinase 14 Yes Yes ↓
hsa-miR-196a RICTOR RPTOR independent companion of MTOR Yes Yes ↓
hsa-miR-96 ATG7 Autophagy related 7 Yes Yes ↑
hsa-miR-15b BCL2 B-cell CLL/lymphoma 2 Yes Yes ↑
hsa-miR-374b VEGFA Vascular endothelial growth factor A Yes Yes ↓
hsa-let-7e ATP2A2 ATPase, Ca++ transporting, cardiac muscle, and slow twitch 2 Yes Yes ↑
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Figure 5: Validation of selected microarray data by qRT-PCR.
Statistically significant difference between propofol and H/R is
indicated by ∗𝑃 < 0.05 (𝑛 = 4).
showed that hsa-miR-20b, hsa-miR-30b, hsa-miR-96, and
hsa-miR-196a may target autophagy-associated genes ULK1,
Becline-1, ATG7 andRictor respectively. Hsa-miR-15b or hsa-
miR-374b may target anti-apoptosis- or proliferation-related
genes. Hsa-miR-7e may target mitochondria-associated gene
(Table 1). All of the reciprocally expressed miRNAs and
proteins were predicted by two of the algorithms (Table 1).
MTOR inhibition is directly involved in autophagy induction
[18, 19]. We found that Hsa-miR-20b, hsa-miR-196 and hsa-
miR-15bmight be the key regulators of autophagy,mTOR and
anti-apoptosis pathway in the protective effects of propofol on
H/R injury, respectively. The miRNA-target gene interaction
networks related to the autophagy andmTOR pathway which
we predicted previously are shown in Figure 6. The upreg-
ulated miRNAs hsa-miR-20b showed the 10 target mRNAs
when autophagy pathway is concerned, while hsa-miR-30b is
also importantly related to autophagy pathway. Hsa-miR-96
and hsa-miR-196a were predicted to target mTOR pathway
related genes (Figure 6).
3. Discussion
H/R-associated cell injury may involve oxidative stress-
induced damage, through formation of reactive oxygen
species (ROS). As potent oxidizing and reducing agents, ROS
directly damage the endothelium cellular membrane through
lipid peroxidation and reductase inhibition [20]. ROS also
upregulate the expression of cell adhesion molecules, induce
transcription of cytokines, and subsequently stimulate the
activation and chemotaxis of neutrophils, which can lead to
the death of the endothelial cells [21].
Propofol is structurally similar to the endogenous antiox-
idant vitamin E and exhibits antioxidant activities [22].
It has a protective effect against oxidative stress-mediated
cell injuries [23]. Propofol prevents reactive oxygen species
(ROS) such as hydrogen peroxide (H
2
O
2
)-induced cellular
damages in cultured endothelial cells and cardiac cells in vitro
[24, 25] and in heartswith ischemia/reperfusion injury in vivo
[10].
To date, only a few studies concerning regulation of
propofol-mediated cellular protection by microRNA have
been reported. Large scale and systemic profiling of key node
microRNAs in H/R treated with P-PostH have not been con-
ducted. Consistent with previous results, our study also found
the protective effect of propofol against the H/R injury in
HUVECs. In order to reveal critical microRNAs involved in
this process, we firstly evaluated the miRNA expression pro-
file in the propofol-postconditioned H/R injury of HUVEC
cells to reveal the potential role of miRNAs in the protective
effect. We found a set of differently expressed miRNAs, with
6 downregulated and 8 upregulated miRNAs in Propofol-
postconditioned groupswhen compared toH/R groups. qRT-
PCR of hsa-miR-30b, hsa-miR-20b, hsa-miR-15b, hsa-let-
7e, hsa-miR-374b, and hsa-miR-196a further validated the
reliability of the microarray result.
In order to gain insight into the function of miRNAs,
GO term and KEGG pathway annotation were applied to
their target gene pool. KEGG annotation showed a significant
change with the autophagy and mTOR signaling pathway in
the P-PostH group compared with the H/R group. Further
investigation of the miRNA-gene network of these two path-
ways shows that hsa-miR-20, hsa-miR-30b, and hsa-miR-
196a might be the key regulators of autophagy and mTOR
pathway, respectively.
Autophagy is an evolutionary conserved process involved
in degradation of long-lived or damaged proteins and
organelles [26–28]. A previous study showed that propofol
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Figure 6: miRNA-gene interaction networks of autophagy and mTOR pathway. Red box nodes represent miRNA that are upregulated in
propofol group. Blue represent downregulated ones and green cycle nodes represent mRNA. Edges show the inhibitory effect of miRNA on
mRNA.
protects the autophagic cell death induced by the myocardial
I/R injury [14]. Beclin-1 and ATG5 were also shown to be
target genes of hsa-miR-30b [29], which were confirmed
by our study. Further experiments are needed to probe the
detailed mechanism. We also revealed other differentially
expressed miRNAs in P-PostH when compared with H/R
group which may regulate the MAPK signaling pathway and
apoptosis, such as hsa-miR-20b and hsa-miR-15b [30–33].
In conclusion, our study, for the first time, systematically
studied the microRNA profiling in P-PostH-treated H/R
HUVEC cells and revealed some miRNAs that differentially
expressed in P-PostH H/R induced cell injury. Their regu-
latory roles in the autophagy and anti-apoptosis pathways
may be involved in the protective effects of the propofol
against H/R injury. The low expression of hsa-miR-30b and
hsa-miR-20b may lead to the abnormal upregulation of
autophagy-related proteins, induce excessive autophagy, and
contribute to the cell death. Confirmation and elucidation of
this mechanism requires further study. Present results also
point to several exciting directions for future research. Each
possible miRNA-gene pair we identified is a strong candidate
for a major study to definitively confirm the presence of
specific miRNA-gene interactions, thus creating a more
detailed picture of the effects of propofol.
4. Materials and Methods
4.1. Reagents and Antibodies. Propofol was purchased from
Sigma Chemical to exclude the influence of lipid emul-
sion. Regents include Dulbecco’s modified Eagle’s medium
(DMEM), newborn calf serum (NCS), penicillin, strepto-
mycin, trypsin-EDTA (GIBCO Laboratories, Grand Island,
New York, USA), dimethylsulfoxide (DMSO), Annexin V-
FITC apoptosis detection kit, and CCK-8 cell counting kit.
Propofol was dissolved inDMSO and further diluted in phos-
phate buffered saline (PBS). The final DMSO concentration
was 0.1%, which did not affect either cell function or the
assay system. The following primary antibodies were used in
this study: anti-beta-Actin antibody (Santa Cruz, sc-47778),
anti-LC3B polyclonal antibody (Sigma, L7543), anti-LC3
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polyclonal antibody (MBL, PM036), anti-TOM20 (FL-145)
(Santa Cruz, sc-11415).
4.2. HUVEC Cell Culture. HUVECs were isolated from
fresh human umbilical cord veins by collagenase digestion
according to a modified technique described by Jaffe et al.
[34]. Briefly, HUVECs were cultured at 37∘C in a 95%O
2
and
5% CO
2
humidified atmosphere in DMEM supplemented
with 20% fetal bovine serum, 100𝜇g/mL streptomycin, and
100 IU/mL penicillin.TheHUVECs were subcultured nine to
ten days later.
4.3. Construction of an In Vitro Cellular Propofol Posthypoxia
Treatment H/R Model. For hypoxia, the culture media was
replaced by glucose and serum free DMEM balanced in
normal incubator in 30 minutes and the HUVEC cells
were then placed in hypoxic conditions which were created
by a small enclosed humidified plexiglass chamber filled
with 94% N
2
, 5% CO
2
, and 1% O
2
at 37∘C for 12 h. After
hypoxia, the medium was washed off, and the HUVECs
were returned to the maintenancemedium (NCS-DMEM) in
normal incubator with 5% CO
2
and 95% N
2
for 4 h. At the
same time, prepared propofol was added to the medium to
different concentrations (25𝜇mol/L–150 𝜇mol/L). Clinically
relevant blood concentration of propofol is approximately
17–62𝜇mol/L for the maintenance of satisfactory anaesthesia
[11]. The blood concentration of bolus injection of propofol
can reach 56 𝜇mol/L. Therefore, we consider 25–100𝜇mol/L
as the range of clinically relevant concentrations and increas-
ing propofol concentrations were designed as 25, 50, 100, and
150𝜇mol/L, respectively (Figure 1).
4.4. Cell Viability Assay. The cellular viability was evaluated
using a CCK-8 kit. Cells were plated at 1 ∗ 104 cells per
well in 96-well plates and treated with H/R and various
concentrations of propofol posthypoxia treatment. Each con-
centration of propofol (0–150𝜇mol/L) was repeated in 6
wells. Meanwhile, increasing concentrations of propofol were
given to non-H/R cells for 4 h. After the radiation exposure,
the cells werewashed twicewith PBS and incubatedwith 1mL
culture medium, which contained 10% CCK-8 solution, for
2 h at 37∘C. The absorbance was measured by a multimode
microplate reader at 450 nm. The cellular viability (%) was
calculated using the formula [(As − Ab)/(Ac − Ab)] ∗ 100%.
As: the absorbance of the well containing supernatant from
exposure or sham-exposure dishes; Ac: the absorbance of the
well containing supernatant from the normal control; Ab: the
absorbance of the well containing culture medium with 10%
CCK-8 solution.
4.5. Detection of Apoptosis. To quantify apoptosis, HUVECs
were stained with Annexin V-FITC and propidium iodide.
Prepared cells were washed twice with cold PBS and resus-
pended in 500mL binding buffer. Fivemicrolitres of Annexin
V-FITC and 5mL of propidium iodide (1mg/mL) were then
added to these cells, which were analysed with a FACSCal-
ibur flow cytometer. Early apoptotic cells were positive for
Annexin V and negative for propidium iodide, whereas late
apoptotic dead cells displayed both high Annexin V and
propidium iodide labelling.
4.6. Western Blotting. The expressions of apoptosis related
proteins and LC3 were determined by Western blot analysis.
The whole cell lysates were prepared in RIPA buffer (50mM
Tris HCl, pH 8, 150mMNaCl, 1% Nonidet P-40, 0.1% SDS,
and 1% Triton X-100 plus proteinase inhibitors; Sigma).
Protein concentrationwas determined by Bradford assay, and
samples containing 30 ug were separated by 12% SDS-PAGE.
Proteins were transferred to nitrocellulose membranes. After
membranes were blocked in 5% nonfat milk in 20mMTris-
HCl, 150mMNaCl, and 0.05% Tween 20 for 1 hr at room
temperature, the membranes were incubated overnight at
4∘C with different primary monoclonal antibodies; 𝛽-actin
antibody was used as a loading control.Themembranes were
then incubated with secondary antibody conjugated to
horseradish peroxide for 1 hr at room temperature and were
exposed to enhanced chemiluminescence reagents. Densito-
metric analysiswas performed to quantify the signal intensity.
4.7. Immunofluorescence. Cells were grown to 70% conflu-
ence on a coverslip. After treatment, cells were washed twice
with PBS (Shanghai Sangon Biotech) and fixed with freshly
prepared 4% paraformaldehyde at 37∘C for 15min. Antigen
accessibility was increased by treatment with 0.1% Triton X-
100 (Shanghai Sangon Biotech). After blocking with 1% BSA,
cells were incubated with primary antibodies for 1 h at room
temperature, and, after washing with PBS, stained with a
secondary antibody for a further 50min at room temperature.
Cell images were captured with a TCS SPF5 II Leica confocal
microscope.
4.8. RNA Extraction and miRNA Microarray Analysis. Total
RNA containing small RNA was extracted from H/R groups
and P-PostH groups in HUVECs by using the Trizol reagent
(Invitrogen) and purified with mirVana miRNA Isolation
Kit (Ambion, Austin, TX, USA) according to manufacture’s
protocol. The purity and concentration of RNA were deter-
mined from OD260/280 readings using spectrophotometer
(NanoDrop ND-1000). RNA integrity was determined by 1%
formaldehyde denaturing gel electrophoresis. The miRNA
profilingwas performedusingAgilentmiRNAarray.TheAgi-
lent array was designed with eight identical arrays per slide
(8 × 60K format), with each array containing probes inter-
rogating 1887 human mature miRNAs and 121 human virus
relatedmiRNAs, both frommiRBase R18.0. EachmiRNAwas
detected by probes repeat for 30 times.
Microarray experiments were conducted according to
the manufacturer’s instructions. Briefly, the miRNAs were
labeled using the AgilentmiRNA labeling reagent. Total RNA
(100 ng)was dephosphorylated and ligatedwith pCp-Cy3, the
labeled RNA was purified and hybridized to miRNA arrays.
Images were scanned with the Agilent microarray scanner
(Agilent), gridded, and analyzed using Agilent feature extrac-
tion software version 10.10.
4.9. Validation of Selected Microarray Data by qRT-PCR. The
differentially expressed miRNAs between H/R and P-PostH
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Table 2: Primers used in qRT-PCR.
Gene Annealing temperature ∘C Number of gene primer (5󸀠 → 3󸀠) Accession number
U6 60 F: 5
󸀠CTCGCTTCGGCAGCACATATACT3󸀠 NR 004394.1
R: 5󸀠CGAATTTGCGTGTCATCCTTGCG3󸀠
hsa-miR-30b 60 F: 5
󸀠CGCTGTAAACATCCTACACTCA3󸀠 MIMAT0000420
R: 5󸀠GCAGGGTCCGAGGTATTC3󸀠
Hsa-miR-15b-5P 60 F: 5
󸀠ATGGTTCGTGGGTAGCAGCACATCATGGTTTACA3󸀠 MIMAT0000417
R: 5󸀠GCAGGGTCCGAGGTATTC3󸀠
Has-miR-196a-5p 60 F: 5
󸀠ATGGTTCGTGGGTAGGTAGTTTCATGTTGTTGG3󸀠 MIMAT0000226
R: 5󸀠GCAGGGTCCGAGGTATTC3󸀠
Hsa-miR-374b-5P 60 F: 5
󸀠CGTGGGATATAATACAACCTGCTAAGTG3󸀠 MIMAT0004955
R: 5󸀠CTCAACTGGTGTCGTGGA3󸀠
Hsa-miR-20b-5P 60 F: 5
󸀠ATGGTTCGTGGGCAAAGTGCTCATAGTGCAGGTAG3󸀠 MIMAT0001413
R: 5󸀠CTCAACTGGTGTCGTGGA3󸀠
Hsa-let-7e 60 F: 5
󸀠CGCTGAGGTAGGAGGTTGTA3󸀠 MIMAT0000066
R: 5󸀠GCAGGGTCCGAGGTATTC3󸀠
F: forward primer; R: reverse primer.
miRNA number and sequence of a specific miRNA can be obtained from miRBase sequence.
levels were determined by qRT-PCR as described [35, 36].
Briefly, RNAs from HUVECs were isolated with mirVana
miRNA Isolation Kit (Ambion). QRT-PCR for miRNAs was
performed on cDNA generated from 50 ng of total RNA
using the protocol of the mirVana quantitative real-time
polymerase chain reaction miRNA detection kit (Ambion).
As an internal control, U6 was used for miRNAs template
normalization. Fluorescent signals were normalized to an
internal reference, and the threshold cycle (Ct) was set within
the exponential phase of the polymerase chain reaction.
The relative gene expression was calculated by comparing
cycle times for each target polymerase chain reaction. The
target polymerase chain reaction Ct values were normalized
by subtracting the U6 Ct value, which provided the ΔCt
value. The relative expression level between treatments was
then calculated using the following equation: relative gene
using the ΔΔCt method with normalization to U6 rRNA
endogenous control.The primers used for RT-PCR are shown
in Table 2.
4.10. Target Gene Prediction. Prediction of miRNA target
prediction can be performed by computational algorithms
due to their base-pairing rules between miRNA and mRNA
target sites, location of binding sequences within the target’s
3󸀠UTR, and conservation of target binding sequences within
related genomes. In our study, genes that were predicted by
TargetScan v5.1 (http://www.targetscan.org/) andMiranda v5
(http://www.mirbase.org/) were regarded as potential targets
of a certain miRNA.
4.11. Bioinformatic Analysis of Differentially Expressed miR-
NAs. Gene Ontology (GO) analysis was applied in order
to organize genes into hierarchical categories and uncover
the miRNA gene regulatory network on the basis of bio-
logical process, cellular component, and molecular function.
We divided the differentially expressed miRNAs into two
groups (H/R upregulated and H/R downregulated) and
mapped these two groups to each node of the GO
database. The miRNAs corresponding to every node were
counted by GSEABase package on the R statistic platform
(http://www.r-project.org/). We also analyzed the potential
target gene related pathways using GenMAPP v2.1 based on
Kyoto Encyclopedia ofGenes andGenomes (KEGG) pathway
database.The enrichment𝑃-value of the target genes involved
in every pathwaywas calculated. Afterward, we integrated the
regulatory interactions between the genes and miRNAs. We
analyzed two different interactions simultaneously: (1) data
from KEGG database describing the relationship between
genes, including enzyme-enzyme relation, protein-protein
interaction, and gene expression interaction (KEGGSOAP
software package (http://www.bioconductor.org/packages/
2.4/bioc/html/KEGGSOAP.html)) and (2) protein-protein
interactions verified by high-flux experiments (the MIPS
mammalian protein-protein interaction database: http://mips
.helmholtz-muenchen.de/proj/ppi/). Then, we integrated the
results into the gene network, and displayed the figure with
the software Medusa 21 (data not shown). Finally, we built
certain pathway-related networks using predicted targets for
the miRNAs to identify critical miRNAs that might modulate
the pathways according to the miRNA degree.
Conflict of Interests
The authors declare that they have no conflict of interests.
Acknowledgments
This work is supported by the National Natural Science
Foundation of China (81270916, 31301104) and also by the
Scientific Research Start-up grant from Guangdong Medical
College (XB1342, 701B01206).
10 Oxidative Medicine and Cellular Longevity
References
[1] H. K. Eltzschig and C. D. Collard, “Vascular ischaemia and
reperfusion injury,” British Medical Bulletin, vol. 70, pp. 71–86,
2004.
[2] Z. Huang, X. Zhong, M. G. Irwin et al., “Synergy of isoflurane
preconditioning and propofol postconditioning reduces myo-
cardial reperfusion injury in patients,” Clinical Science, vol. 121,
no. 2, pp. 57–69, 2011.
[3] G. Tan and M. G. Irwin, “Recent advances in using propofol
by non-anesthesiologists,” F1000 Medicine Reports, vol. 2, no. 1,
article 79, 2010.
[4] S. F. Hughes, M. J. Cotter, S. A. Evans, K. P. Jones, and R. A.
Adams, “Role of leucocytes in damage to the vascular endothe-
lium during ischaemia-reperfusion injury,” British Journal of
Biomedical Science, vol. 63, no. 4, pp. 166–170, 2006.
[5] V. V. Shuvaev and V. R. Muzykantov, “Targeted modulation of
reactive oxygen species in the vascular endothelium,” Journal of
Controlled Release, vol. 153, no. 1, pp. 56–63, 2011.
[6] Z. Xia, Z. Huang, and D. M. Ansley, “Large-dose propofol
during cardiopulmonary bypass decreases biochemicalmarkers
ofmyocardial injury in coronary surgery patients: a comparison
with isoflurane,” Anesthesia and Analgesia, vol. 103, no. 3, pp.
527–532, 2006.
[7] T. Radovits, J. Zotkina, L. N. Lin, M. Karck, and G. Szabo´,
“Endothelial dysfunction after hypoxia-reoxygenation: do in
vitro models work?” Vascular Pharmacology, vol. 51, no. 1, pp.
37–43, 2009.
[8] S. Dohgu, T. Nishioku, N. Sumi et al., “Adverse effect of
cyclosporin A on barrier functions of cerebral microvascular
endothelial cells after hypoxia-reoxygenation damage in vitro,”
Cellular and Molecular Neurobiology, vol. 27, no. 7, pp. 889–899,
2007.
[9] B. Wang, J. Shravah, H. Luo, K. Raedschelders, D. D. Y.
Chen, and D. M. Ansley, “Propofol protects against hydrogen
peroxide-induced injury in cardiacH9c2 cells via Akt activation
and Bcl-2 up-regulation,” Biochemical and Biophysical Research
Communications, vol. 389, no. 1, pp. 105–111, 2009.
[10] Y. C. Jin,W. Kim, Y.M. Ha et al., “Propofol limits rat myocardial
ischemia and reperfusion injury with an associated reduction in
apoptotic cell death in vivo,”Vascular Pharmacology, vol. 50, no.
1-2, pp. 71–77, 2009.
[11] D. R. Cui, L. Wang, W. Jiang, A. H. Qi, Q. H. Zhou, and
X. L. Zhang, “Propofol prevents cerebral ischemia-triggered
autophagy activation and cell death in the rat hippocampus
through the NF-kappaB/p53 signaling pathway,” Neuroscience,
vol. 246, pp. 117–132, 2013.
[12] D. Cui, L. Wang, A. Qi, Q. Zhou, X. Zhang, and W. Jiang,
“Propofol prevents autophagic cell death following oxygen
and glucose deprivation in PC12 cells and cerebral ischemia-
reperfusion injury in rats,” PLoS ONE, vol. 7, no. 4, Article ID
e35324, 2012.
[13] S. Lee, K. Kim, Y. H. Kim et al., “Preventive role of propofol
in hypoxia/reoxygenation-induced apoptotic H9c2 rat cardiac
myoblast cell death,” Molecular Medicine Reports, vol. 4, no. 2,
pp. 351–356, 2011.
[14] H. S. Noh, I. W. Shin, J. H. Ha, Y. S. Hah, S. M. Baek, and D.
R. Kim, “Propofol protects the autophagic cell death induced
by the ischemia/reperfusion injury in rats,”Molecules and Cells,
vol. 30, no. 5, pp. 455–460, 2010.
[15] V. Ambros, “MicroRNA pathways in flies and worms: growth,
death, fat, stress, and timing,” Cell, vol. 113, no. 6, pp. 673–676,
2003.
[16] K. K. H. Farh, A. Grimson, C. Jan et al., “Biochemistry: the
widespread impact of mammalian microRNAs on mRNA
repression and evolution,” Science, vol. 310, no. 5755, pp. 1817–
1821, 2005.
[17] C. Yin, X. Wang, and R. C. Kukreja, “Endogenous microRNAs
induced by heat-shock reduce myocardial infarction following
ischemia-reperfusion inmice,” FEBS Letters, vol. 582, no. 30, pp.
4137–4142, 2008.
[18] J. J. Jaboin, E. T. Shinohara, L. Moretti, E. S. Yang, J. M. Kamin-
ski, and B. Lu, “The role of mTOR inhibition in augmenting
radiation induced autophagy,” Technology in Cancer Research
and Treatment, vol. 6, no. 5, pp. 443–447, 2007.
[19] B. Ravikumar, C. Vacher, Z. Berger et al., “Inhibition of mTOR
induces autophagy and reduces toxicity of polyglutamine
expansions in fly and mouse models of Huntington disease,”
Nature Genetics, vol. 36, no. 6, pp. 585–595, 2004.
[20] H. Y. Sun, N. P. Wang, F. Kerendi et al., “Hypoxic postcon-
ditioning reduces cardiomyocyte loss by inhibiting ROS gen-
eration and intracellular Ca2+ overload,” American Journal of
Physiology—Heart and Circulatory Physiology, vol. 288, no. 4,
pp. H1900–H1908, 2005.
[21] S. Grotti and T. Gori, “Endothelium, ischemia and the good side
of oxygen free radicals,” Clinical Hemorheology and Microcircu-
lation, vol. 39, no. 1–4, pp. 197–203, 2008.
[22] I. Gu¨lc¸in, H. A. Alici, and M. Cesur, “Determination of in vitro
antioxidant and radical scavenging activities of propofol,”
Chemical and Pharmaceutical Bulletin, vol. 53, no. 3, pp. 281–
285, 2005.
[23] I. Vasileiou, T. Xanthos, E. Koudouna et al., “Propofol: a review
of its non-anaesthetic effects,” European Journal of Pharmacol-
ogy, vol. 605, no. 1-3, pp. 1–8, 2009.
[24] J. J. Xu and Y. L. Wang, “Propofol attenuation of hydrogen
peroxide-mediated oxidative stress and apoptosis in cultured
cardiomyocytes involves haeme oxygenase-1,” European Journal
of Anaesthesiology, vol. 25, no. 5, pp. 395–402, 2008.
[25] B. Wang, T. Luo, D. Chen, and D. M. Ansley, “Propofol reduces
apoptosis and up-regulates endothelial nitric oxide synthase
protein expression in hydrogen peroxide-stimulated human
umbilical vein endothelial cells,” Anesthesia and Analgesia, vol.
105, no. 4, pp. 1027–1033, 2007.
[26] N. Mizushima, “Physiological functions of autophagy,” Current
Topics in Microbiology and Immunology, vol. 335, no. 1, pp. 71–
84, 2009.
[27] L. Liu, D. Feng, G. Chen et al., “Mitochondrial outer-membrane
protein FUNDC1 mediates hypoxia-induced mitophagy in
mammalian cells,”Nature Cell Biology, vol. 14, no. 2, pp. 177–185,
2012.
[28] D. Feng, L. Liu, Y. Zhu, and Q. Chen, “Molecular signaling
toward mitophagy and its physiological significance,” Experi-
mental Cell Research, vol. 319, pp. 1697–1705, 2013.
[29] W. Pan, Y. Zhong, C. Cheng et al., “MiR-30-regulated autophagy
mediates angiotensin II-induced myocardial hypertrophy,”
PLoS ONE, vol. 8, Article ID e53950, 2013.
[30] S. Cascio, A. D’Andrea, R. Ferla et al., “miR-20b modulates
VEGF expression by targeting HIF-1𝛼 and STAT3 in MCF-7
breast cancer cells,” Journal of Cellular Physiology, vol. 224, no.
1, pp. 242–249, 2010.
Oxidative Medicine and Cellular Longevity 11
[31] Z. Lei, B. Li, Z. Yang et al., “Regulation of HIF-1𝛼 and VEGF by
miR-20b tunes tumor cells to adapt to the alteration of oxygen
concentration,” PLoS ONE, vol. 4, no. 10, Article ID e7629, 2009.
[32] F. An, B. Gong, H. Wang et al., “miR-15b and miR-16 regulate
TNF mediated hepatocyte apoptosis via BCL2 in acute liver
failure,” Apoptosis, vol. 17, no. 7, pp. 702–716, 2012.
[33] L. Xia, D. Zhang, R. Du et al., “miR-15b and miR-16 modulate
multidrug resistance by targeting BCL2 in human gastric cancer
cells,” International Journal of Cancer, vol. 123, no. 2, pp. 372–
379, 2008.
[34] E. A. Jaffe, R. L. Nachman, C. G. Becker, and C. R.Minick, “Cul-
ture of human endothelial cells derived from umbilical veins.
Identification by morphologic and immunologic criteria,” Jour-
nal of Clinical Investigation, vol. 52, no. 11, pp. 2745–2756, 1973.
[35] R. Ji, Y. Cheng, J. Yue et al., “MicroRNA expression signature
and antisense-mediated depletion reveal an essential role of
MicroRNA in vascular neointimal lesion formation,” Circula-
tion Research, vol. 100, no. 11, pp. 1579–1588, 2007.
[36] Y. Lin, X. Liu, Y. Cheng, J. Yang, Y. Huo, and C. Zhang,
“Involvement of MicroRNAs in hydrogen peroxide-mediated
gene regulation and cellular injury response in vascular smooth
muscle cells,” Journal of Biological Chemistry, vol. 284, no. 12, pp.
7903–7913, 2009.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
